Sorbera Chiara, Brigandì Amelia, Cimino Vincenzo, Bonanno Lilla, Ciurleo Rosella, Bramanti Placido, Di Lorenzo Giuseppe, Marino Silvia
IRCCS Centro Neurolesi "Bonino Pulejo", Messina, Italy.
PLoS One. 2021 May 6;16(5):e0251313. doi: 10.1371/journal.pone.0251313. eCollection 2021.
On March 2019 the World Health Organization declared Coronavirus disease (COVID-19) pandemic. Several recent reports disclose that the outcome of the infection is related to age, sex and can be influenced by underlying clinical conditions. Parkinson's disease (PD) and other parkinsonisms are the most common chronic disease which can cause, directly or indirectly, the patient to be more exposed to other diseases, mostly respiratory system's ones. Our primary outcome is to evaluate if PD patients are more susceptible than non-PD to take COVID-19 infection. Second, to detect if the infection course is worse in PD-COVID+ patients versus non-PD. This is a retrospective observational study on a cohort of 18 patients (13 PD- 5 non-PD), hospitalized in a Rehabilitative Unit during the occurrence of SARS-CoV2 epidemic outbreak. All patients performed laboratory tests, lung Computed Tomography (CT) and have been tested for COVID-19 thorough pharyngeal swab. PD and non-PD groups were comparable for age, gender and Hoehn and Yahr stage. Seventy-seven (77)% of PD and 60% of non-PD resulted positive for COVID-19. PD-COVID+ and PD-COVID- did not differ for age, disease duration and L-dopa daily dose. PD COVID-19+ subjects were mainly asymptomatic (50%) while non-PD ones were all symptomatic, mostly with respiratory difficulties. PD doesn't seem to be a risk factor to take SARS-COV2 infection, even if our study is related to a limited sample size. Our results, together with those of other recent studies, highlight the need to evaluate the actual susceptibility of patients with Parkinson's disease to develop COVID-19 disease, and how the infection may influence the risk of clinical worsening and increase of mortality.
2019年3月，世界卫生组织宣布冠状病毒病（COVID-19）为大流行病。最近的几份报告显示，感染的结果与年龄、性别有关，并且可能受到潜在临床状况的影响。帕金森病（PD）和其他帕金森综合征是最常见的慢性疾病，可直接或间接导致患者更容易接触其他疾病，尤其是呼吸系统疾病。我们的主要研究结果是评估帕金森病患者是否比非帕金森病患者更容易感染COVID-19。其次，检测PD-COVID+患者与非PD患者相比，感染过程是否更严重。这是一项对18名患者（13名帕金森病患者 - 5名非帕金森病患者）进行的回顾性观察研究，这些患者在SARS-CoV2疫情爆发期间在康复科住院。所有患者均进行了实验室检查、肺部计算机断层扫描（CT），并通过咽拭子进行了COVID-19检测。帕金森病组和非帕金森病组在年龄、性别和Hoehn和Yahr分期方面具有可比性。77%的帕金森病患者和60%的非帕金森病患者COVID-19检测呈阳性。PD-COVID+组和PD-COVID-组在年龄、病程和左旋多巴每日剂量方面没有差异。帕金森病COVID-19+患者主要无症状（50%），而非帕金森病患者均有症状，主要表现为呼吸困难。帕金森病似乎不是感染SARS-CoV2的危险因素，即使我们的研究样本量有限。我们的结果与其他近期研究的结果共同强调，有必要评估帕金森病患者感染COVID-19疾病的实际易感性，以及感染可能如何影响临床恶化风险和死亡率增加。
